Antibiotics Should Be One Step On FDA’s “Critical Path,” Lilly VP Says

Antibiotic development is an ideal FDA "Critical Path" opportunity due to the lack of antitrust concerns surrounding the therapeutic category, Lilly VP-Scientific Affairs Gail Cassell, PhD, told the FDA Science Board Advisory Committee April 22